FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226366416> ?p ?o ?g. }

• W4226366416 endingPage "e0257972" @default.
• W4226366416 startingPage "e0257972" @default.
• W4226366416 abstract "Cancer immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), represents a breakthrough in cancer treatment, resulting in unprecedented results in terms of overall and progression-free survival. Discovery and development of novel anti PD-1 inhibitors remains a field of intense investigation, where novel monoclonal antibodies (mAbs) and novel antibody formats (e.g., novel isotype, bispecific mAb and low-molecular-weight compounds) are major source of future therapeutic candidates. HLX10, a fully humanized IgG4 monoclonal antibody against PD-1 receptor, increased functional activities of human T-cells and showed in vitro, and anti-tumor activity in several tumor models. The combined inhibition of PD-1/PDL-1 and angiogenesis pathways using anti-VEGF antibody may enhance a sustained suppression of cancer-related angiogenesis and tumor elimination. To elucidate HLX10's mode of action, we solved the structure of HLX10 in complex with PD-1 receptor. Detailed epitope analysis showed that HLX10 has a unique mode of recognition compared to the clinically approved PD1 antibodies Pembrolizumab and Nivolumab. Notably, HLX10's epitope was closer to Pembrolizumab's epitope than Nivolumab's epitope. However, HLX10 and Pembrolizumab showed an opposite heavy chain (HC) and light chain (LC) usage, which recognizes several overlapping amino acid residues on PD-1. We compared HLX10 to Nivolumab and Pembrolizumab and it showed similar or better bioactivity in vitro and in vivo, providing a rationale for clinical evaluation in cancer immunotherapy." @default.
• W4226366416 created "2022-05-05" @default.
• W4226366416 creator A5001699296 @default.
• W4226366416 creator A5011547157 @default.
• W4226366416 creator A5013345563 @default.
• W4226366416 creator A5013506995 @default.
• W4226366416 creator A5014898667 @default.
• W4226366416 creator A5019052048 @default.
• W4226366416 creator A5040176929 @default.
• W4226366416 creator A5046055457 @default.
• W4226366416 creator A5047604705 @default.
• W4226366416 creator A5050372269 @default.
• W4226366416 creator A5051543327 @default.
• W4226366416 creator A5051659272 @default.
• W4226366416 creator A5052024256 @default.
• W4226366416 creator A5056168007 @default.
• W4226366416 creator A5060932450 @default.
• W4226366416 creator A5062282859 @default.
• W4226366416 creator A5064342343 @default.
• W4226366416 creator A5081397797 @default.
• W4226366416 creator A5084619384 @default.
• W4226366416 creator A5086722262 @default.
• W4226366416 creator A5087803810 @default.
• W4226366416 date "2021-12-31" @default.
• W4226366416 modified "2023-10-06" @default.
• W4226366416 title "Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy" @default.
• W4226366416 cites W1749548564 @default.
• W4226366416 cites W1996192954 @default.
• W4226366416 cites W2016983859 @default.
• W4226366416 cites W2053353274 @default.
• W4226366416 cites W2107752337 @default.
• W4226366416 cites W2156906256 @default.
• W4226366416 cites W2473759462 @default.
• W4226366416 cites W2530034556 @default.
• W4226366416 cites W2586232813 @default.
• W4226366416 cites W2606939149 @default.
• W4226366416 cites W2740931940 @default.
• W4226366416 cites W2785803176 @default.
• W4226366416 cites W2790574591 @default.
• W4226366416 cites W2792254065 @default.
• W4226366416 cites W2794577178 @default.
• W4226366416 cites W2898701288 @default.
• W4226366416 cites W2941109595 @default.
• W4226366416 cites W3009943258 @default.
• W4226366416 cites W3011027479 @default.
• W4226366416 cites W3011824547 @default.
• W4226366416 cites W3031825285 @default.
• W4226366416 cites W3084409519 @default.
• W4226366416 cites W3087169700 @default.
• W4226366416 cites W3130927738 @default.
• W4226366416 doi "https://doi.org/10.1371/journal.pone.0257972" @default.
• W4226366416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34972111" @default.
• W4226366416 hasPublicationYear "2021" @default.
• W4226366416 type Work @default.
• W4226366416 citedByCount "10" @default.
• W4226366416 countsByYear W42263664162022 @default.
• W4226366416 countsByYear W42263664162023 @default.
• W4226366416 crossrefType "journal-article" @default.
• W4226366416 hasAuthorship W4226366416A5001699296 @default.
• W4226366416 hasAuthorship W4226366416A5011547157 @default.
• W4226366416 hasAuthorship W4226366416A5013345563 @default.
• W4226366416 hasAuthorship W4226366416A5013506995 @default.
• W4226366416 hasAuthorship W4226366416A5014898667 @default.
• W4226366416 hasAuthorship W4226366416A5019052048 @default.
• W4226366416 hasAuthorship W4226366416A5040176929 @default.
• W4226366416 hasAuthorship W4226366416A5046055457 @default.
• W4226366416 hasAuthorship W4226366416A5047604705 @default.
• W4226366416 hasAuthorship W4226366416A5050372269 @default.
• W4226366416 hasAuthorship W4226366416A5051543327 @default.
• W4226366416 hasAuthorship W4226366416A5051659272 @default.
• W4226366416 hasAuthorship W4226366416A5052024256 @default.
• W4226366416 hasAuthorship W4226366416A5056168007 @default.
• W4226366416 hasAuthorship W4226366416A5060932450 @default.
• W4226366416 hasAuthorship W4226366416A5062282859 @default.
• W4226366416 hasAuthorship W4226366416A5064342343 @default.
• W4226366416 hasAuthorship W4226366416A5081397797 @default.
• W4226366416 hasAuthorship W4226366416A5084619384 @default.
• W4226366416 hasAuthorship W4226366416A5086722262 @default.
• W4226366416 hasAuthorship W4226366416A5087803810 @default.
• W4226366416 hasBestOaLocation W42263664161 @default.
• W4226366416 hasConcept C121608353 @default.
• W4226366416 hasConcept C126322002 @default.
• W4226366416 hasConcept C159654299 @default.
• W4226366416 hasConcept C195616568 @default.
• W4226366416 hasConcept C203014093 @default.
• W4226366416 hasConcept C2777701055 @default.
• W4226366416 hasConcept C2780030458 @default.
• W4226366416 hasConcept C2780057760 @default.
• W4226366416 hasConcept C2780674031 @default.
• W4226366416 hasConcept C502942594 @default.
• W4226366416 hasConcept C542903549 @default.
• W4226366416 hasConcept C71924100 @default.
• W4226366416 hasConceptScore W4226366416C121608353 @default.
• W4226366416 hasConceptScore W4226366416C126322002 @default.
• W4226366416 hasConceptScore W4226366416C159654299 @default.
• W4226366416 hasConceptScore W4226366416C195616568 @default.
• W4226366416 hasConceptScore W4226366416C203014093 @default.
• W4226366416 hasConceptScore W4226366416C2777701055 @default.

• next